Ultrasound Therapy for Adults with Cardiac Amyloidosis or Without Amyloidosis to Study Heart Function

What this Trial Is About

Researchers are studying cardiac amyloidosis, a condition affecting the heart, by evaluating how ultrasound therapy, called sonotherapy, impacts heart blood flow and function. This pilot clinical study will include subjects with two types of cardiac amyloidosis and a control group without amyloidosis. The study aims to understand changes in heart function before and after sonotherapy treatment. The study will enroll 70 participants divided into three groups 30 with light chain cardiac amyloidosis, 30 with transthyretin cardiac amyloidosis, and 10 without amyloidosis. All participants will receive sonotherapy involving high mechanical index ultrasound combined with an intravenous contrast agent called Definity. Each participant will undergo tests including 2D echocardiography at rest and perfusion PET scans with N-13 ammonia or rubidium-82. During the study, participants will have their heart blood flow, systolic function, and diastolic function measured before and after sonotherapy. These assessments will take place within one day. The research team will monitor heart function changes using imaging and biomarkers. The total participation duration aligns with these evaluations, focusing on short-term effects of sonotherapy in cardiac amyloidosis and control subjects.

Ultrasound Therapy In Cardiac Amyloidosis